TRIM56 acts through the IQGAP1-CDC42 signaling axis to promote glioma cell migration and invasion.

Diffuse invasion is an important factor leading to treatment resistance and a poor prognosis in gliomas. Herein, we found that expression of the tripartite motif containing 56 (TRIM56), a RING-finger domain containing E3 ubiquitin ligase, was markedly higher in glioma than in normal brain tissue, and was significantly correlated with malignant phenotypes and a poor prognosis. In vitro and in vivo experimental studies revealed that TRIM56 promoted the migration and invasion of glioma cells. Mechanistically, TRIM56 was transcriptionally regulated by SP1 and promoted the K48-K63-linked poly-ubiquitination transition of IQGAP1 at Lys-1230 by interacting with it, which in turn promoted CDC42 activation. This mechanism was confirmed to mediate glioma migration and invasion. In conclusion, our study provides insights into the mechanisms through which TRIM56 promotes glioma motility, i.e., by regulating IQGAP1 ubiquitination to promote CDC42 activation, which might be clinically targeted for the treatment of glioma.

Intra-tumoral angiogenesis correlates with immune features and prognosis in glioma.

Gliomas are the most common malignant tumor in the brain. As with other tumors, the progression of glioma depends on intra-tumoral angiogenesis. However, the effect of angiogenesis on gliomas is still not fully understood. In this study, we developed an angiogenesis pathway score using Gene Set Variation Analysis (GSAV) in R to assess the status of intra-glioma angiogenesis in The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA mRNAseq_325, CGGA mRNA-array), and GSE16011 datasets. We found that the angiogenesis pathway score not only accurately predicted the prognosis of glioma patients, but also accurately distinguished the malignant phenotype and immune characteristics of gliomas. In addition, as an independent prognostic factor, the score could predict glioma sensitivity to radiotherapy and chemotherapy. In summary, we used the angiogenesis pathway score to reveal the relationship between glioma angiogenesis and the malignant phenotype, immune characteristics, and prognosis of glioma.

Investigation of gastric microbiota in patients with coronary atherosclerosis disease infected by Helicobacter pylori.

Gastric microbiota may be involved in the pathogenicity of Helicobacter pylori(Hp). In the present study, 30 male patients with coronary atherosclerosis disease (CAD) infected with Hp and 30 healthy male volunteers with Hp infection as the control group were detectedby macrogenomic sequencing for gastric microbiota. According to the diversity of gastric microbiota, the CAD group was further divided into two subgroups: CAD treatment (CAD-T) and CAD fellow-up (CAD-F). Shannon index of CAD-T was significantly lower than that of the control group and CAD-F (P<0.05), Simpson index was significantly higher than that of the control group and CAD-F (P<0.05), and there was no statistical difference between CAD-T and the control group and CAD-F patients in Chao1 and ACE index (P>0.05). There is a difference in the dominant flora between the CAD group and the control group. After Hp eradication, Shannon index of gastric microbiota increased, Simpson index decreased, and there was statistical difference before and after Hp eradication in CAD-T group (P<0.05). There was no significant difference in Chao1 and ACE index between before and after Hp eradication (P>0.05). There is a significant difference in the dominant flora before and after eradication in CAD-T group. There were significant differences in clinical manifestations, endoscopic manifestations and pathological results among the three groups (P<0.05). The diversity of gastric microbiota is closely related to the pathogenicity of Hp,, regardless of dominant flora.

SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.

PURPOSE: To compare the 6-month efficacy of the intravitreal injection of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy (PCV). METHODS: This is a retrospective case-control study involved 79 PCV eyes of 77 patients. The PCV eyes were treated with an intravitreal injection of either ranibizumab (n = 44) or conbercept (n = 35). Three monthly loading doses were injected and followed by retreatment as needed. The best-corrected visual acuity and angiographic characteristics were evaluated after 6 months. RESULTS: The mean logarithm of the minimum angle of resolution best-corrected visual acuity had improved from 0.86 (Snellen equivalent, 20/145) at baseline to 0.70 (Snellen equivalent, 20/100) at 6 months in the conbercept group (P < 0.001), and from 0.74 (Snellen equivalent, 20/110) at baseline to 0.63 (Snellen equivalent, 20/85) at 6 months in the ranibizumab group (P = 0.032), respectively. The central foveal thickness was decreased from 407 ± 146 µm to 230 ± 71 µm in the conbercept group (P < 0.001), and from 394 ± 93 µm to 208 ± 56 µm in the ranibizumab group (P < 0.001). Polyps were completely regressed and in 21 (47.7%) eyes in the conbercept group at 6 months, significant higher than in 10 (28.6%) eyes in the ranibizumab group (P = 0.029). CONCLUSION: Both conbercept and ranibizumab effectively increased the visual acuity and regressed the polyps of PCV eyes. No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.